Skip to main content
NKG2A-Expressing Natural Killer Cells Dominate the Response to Autologous Lymphoblastoid Cells Infected with Epstein-Barr Virus FRONTIERS IN IMMUNOLOGY Hatton, O., Strauss-Albee, D. M., Zhao, N. Q., Haggadone, M. D., Pelpola, J. S., Krams, S. M., Martinez, O. M., Blish, C. A. 2016; 7

Abstract

Epstein-Barr virus (EBV) is a human ?-herpesvirus that establishes latency and lifelong infection in host B cells while achieving a balance with the host immune response. When the immune system is perturbed through immunosuppression or immunodeficiency, however, these latently infected B cells can give rise to aggressive B cell lymphomas. Natural killer (NK) cells are regarded as critical in the early immune response to viral infection, but their role in controlling expansion of infected B cells is not understood. Here, we report that NK cells from healthy human donors display increased killing of autologous B lymphoblastoid cell lines (LCLs) harboring latent EBV compared to primary B cells. Coculture of NK cells with autologous EBV(+) LCL identifies an NK cell population that produces IFN? and mobilizes the cytotoxic granule protein CD107a. Multi-parameter flow cytometry and Boolean analysis reveal that these functional cells are enriched for expression of the NK cell receptor NKG2A. Further, NKG2A(+) NK cells more efficiently lyse autologous LCL than do NKG2A(-) NK cells. More specifically, NKG2A(+)2B4(+)CD16(-)CD57(-)NKG2C(-)NKG2D(+) cells constitute the predominant NK cell population that responds to latently infected autologous EBV(+) B cells. Thus, a subset of NK cells is enhanced for the ability to recognize and eliminate autologous, EBV-infected transformed cells, laying the groundwork for harnessing this subset for therapeutic use in EBV(+) malignancies.

View details for DOI 10.3389/fimmu.2016.00607

View details for Web of Science ID 000389857900001

View details for PubMedID 28018364

View details for PubMedCentralID PMC5156658